Michelly Yanay Rocobado-Pozo ¹ , María Ruiz-Medina ¹ , Ismael Reina-Reina1, Araceli Reyes-Molina ¹ , José Javier Durán-Ávila ¹
1 Estudiante del Grado en Medicina de la Universidad de Granada (UGR)
Celia Manzano-Cruz ² , Lorena Trujillos-Yévenes ² , Alba Casillas-Sánchez ² , Aimar Martínez-López ² , Isabel Barberá- Rodríguez ² , José Manuel Fernández-Fuentes ²
2 Student of the BA in Translation and Interpreting at the University of Granada (UGR)
There are numerous therapeutic alternatives for the treatment of Parkinson’s disease (PD). However, none of this can stop the progression of this disease, although they do have major symptomatic benefit. Thus, interest arises in new therapeutic alternatives such as cell transplantation, glial cell line-derived neurotrophic factor (GDNF) infusion, cell therapy or gene therapy. This review presents a general overview of current therapies used for PD and future lines of research, highlighting the role of gene therapy. The different gene therapy approaches for PD are revised. These include a symptomatic gene therapy, which aims to restore dopamine levels in the brain, and a therapy focused on the modification of the disease, for which the glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) plays a fundamental role. Finally, the authors conclude that these lines of research are still far from clinical application.
Keywords: glial cell line-derived neurotrophic factor, cell therapy, gene therapy, glial cells.